[
  {
    "ts": null,
    "headline": "Revvity Board Declares Quarterly Dividend",
    "summary": "WALTHAM, Mass., October 23, 2025--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.",
    "url": "https://finnhub.io/api/news?id=26083ed308cdf0b02eabb198668fe7ad1616f84bf2582695634b59f432ad2607",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761249900,
      "headline": "Revvity Board Declares Quarterly Dividend",
      "id": 137218629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., October 23, 2025--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.",
      "url": "https://finnhub.io/api/news?id=26083ed308cdf0b02eabb198668fe7ad1616f84bf2582695634b59f432ad2607"
    }
  },
  {
    "ts": null,
    "headline": "Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?",
    "summary": "RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.",
    "url": "https://finnhub.io/api/news?id=fcd73e7893af48f9fdf46d7716bf78b1a9398a2b64d82fc10339abef32c12a9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761220380,
      "headline": "Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?",
      "id": 137198377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.",
      "url": "https://finnhub.io/api/news?id=fcd73e7893af48f9fdf46d7716bf78b1a9398a2b64d82fc10339abef32c12a9d"
    }
  }
]